Tumour cells produce receptor activator of NF-κB ligand (RANKL) in skeletal metastases

Documenti analoghi

• Receptor activator of NF-κB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment
  di: Huang, L, et al.
  Pubblicazione: (2003)
• Receptor Activator of NF-κB Ligand (RANKL) Protects Against Hepatic Ischemia/Reperfusion Injury in Mice
  di: Sakai, Nozomu, et al.
  Pubblicazione: (2012)
• RANKL (Receptor Activator of NFκB Ligand) Produced by Osteocytes Is Required for the Increase in B Cells and Bone Loss Caused by Estrogen Deficiency in Mice
  di: Fujiwara, Yuko, et al.
  Pubblicazione: (2016)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  di: Martin Widschwendter, et al.
  Pubblicazione: (2015-10-01)
• Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
  di: Widschwendter, Martin, et al.
  Pubblicazione: (2015)